FARN:LON
Faron Pharmaceuticals Oy
GBXÂ 30.95
arrow_downward
-0.16%(-0.050) 1D
Nov 4, 4:30:00 PM UTC · GBX
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for FARN...
Open
GBXÂ 30.95
High
GBXÂ 30.95
Low
GBXÂ 30.50
Mkt. cap
63.94M
Avg. vol.
39.53K
Volume
16.18K
52-wk high
GBXÂ 189.89
52-wk low
GBXÂ 29.00
EPS
-GBXÂ 0.10
Shares outstanding
31.03M
No. of employees
36
Open
GBXÂ 30.95
High
GBXÂ 30.95
Low
GBXÂ 30.50
Mkt. cap
63.94M
Avg. vol.
39.53K
Volume
16.18K
52-wk high
GBXÂ 189.89
52-wk low
GBXÂ 29.00
EPS
-GBXÂ 0.10
Shares outstanding
31.03M
No. of employees
36
News stories
From web sources and news partners
Virginia Business
·
32 minutes ago
Accendra Health could be delisted by NYSE
The Motley Fool
·
35 minutes ago
The Nasdaq-100 Is Outperforming Nvidia, Microsoft, Amazon, Meta Platforms, Alphabet, and Tesla This Year. Here's My Favorite Low-Cost ETF to Buy the Dip.
The Washington Post
·
2 hours ago
The S&P 500 climbs after Democrats sweep the midterms
Seeking Alpha
·
34 minutes ago
The Average Performance Of The S&P 500 Under A Divided Government Since 1953
Profile
Faron Pharmaceuticals is a Finnish drug discovery and development company based in Turku, Finland.
The company was founded in 2003 by a group led by Markku Jalkanen, who now acts as the company's Chief Executive Officer. It specialises in the development of treatments for acute organ traumas, vascular damage and cancer immunotherapy.
Its lead product Traumakine has been developed to treat acute respiratory distress syndrome. It is currently undergoing international phase III clinical trials after an open-label, early-phase trial showed promising results in the treatment patients with ARDS. The drug is known to function by enhancing lung CD73 expression and increasing production of anti-inflammatory adenosine, such that vascular leaking and escalation of inflammation are reduced. The U.S. Food and Drug Administration FDA has accepted the proposed protocol design for the next Traumakine study in March 2020. The phase III study is a comparison of efficacy in the treatment of patients with ARDS.
In 2020 Traumakine was selected to take part in the WHO Solidarity trial and REMAP-CAP trials to find drugs for the symptoms of Covid_19. Wikipedia
About Faron Pharmaceuticals Oy